of solid‐core lipid ...Figure 9.2 Toxicity mechanisms of components of gene delivery nanocarriers. ...Figure 9.3 Structures of cationic lipids and ionizable cationic lipids evalu...Figure 9.4 Structures of a few cationic polymers evaluated/being evaluated i...10 Chapter 10Figure 10.1 Types of lipid nanoparticles.Figure 10.2 Toxicity due to nanoparticles.
11 Chapter 11Figure 11.1 Illustrations of carriers nanoparticulated and surface’s functio...
12 Chapter 12Figure 12.1 Illustration of different layers of the skin and various routes ...Figure 12.2 Schematics of different types of nanoformulations used in topica...
13 Chapter 13Figure 13.1 Nanostructured drug delivery systems.Figure 13.2 Nanonutraceuticals – considerations for toxicity and safety asse...
14 Chapter 14Figure 14.1 Nanomaterial's exposure pathways.Figure 14.2 In silico analysis: a computational method for the evaluation of...Figure 14.3 Nanosafety strategy.
15 Chapter 15Figure 15.1 The number of studies on the regulation of biomedical nano‐produ...Figure 15.2 The number of studies on the regulation of biomedical nano‐produ...
16 Chapter 16Figure 16.1 Types of nanotechnology.Figure 16.2 Applications of nanotechnology.
17 Chapter 17Figure 17.1 Assessment of physicochemical attributes of nanomaterials using ...Figure 17.2 Components of safety and health programme.Figure 17.3 Overview of regulatory control over nanotechnology.Figure 17.4 Various regulatory agencies providing guidance on regulation of ...
Guide
4 Preface
9 Index
10 Wiley End User License Agreement
Pages
1 iii
2 iv
3 xiii
4 xiv
5 xv
6 xvi
7 xvii
8 xviii
9 xix
10 xx
11 xxi
12 1
13 3
14 4
15 5
16 6
17 7
18 8
19 9
20 10
21 11
22 12
23 13
24 14
25 15
26 16
27 17
28 18
29 19
30 20
31 21
32
